Paul L Berns bought $20.0M of Kardigan (KARD)
Executed Jun 22, disclosed Jun 24, 2 days later.
Over the 21 trading sessions from the disclosed entry session (Jun 24), the stock returned -0.0% (delay-adjusted); from the execution session (Jun 22), +7.6%. Derived: entry at the session's open, exit at the close 20 sessions later.
Paul L Berns (Director) filed 1 Form 4 report in the trailing twelve months (1 purchase, 0 sales), most often in Kardigan, Inc. (KARD). Across 1 priced purchase filing, the average 21-session return was +7.6% from execution and -0.0% from disclosure (delay-adjusted; derived). The largest single filing was $20.0M of KARD (1,250,000 sh × $16.00, as filed), executed Jun 22.
Healthcare · Kardigan, Inc. operates as a biopharmaceutical company focused on developing medicines for cardiovascular diseases
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→